adUnits.push({
code: ‘Rpp_mundo_actualidad_Nota_Interna1’,
mediaTypes: {
banner: {
sizes: (navigator.userAgent.match(/iPhone|android|iPod/i)) ? [[300, 250], [320, 460], [320, 480], [320, 50], [300, 100], [320, 100]] : [[300, 250], [320, 460], [320, 480], [320, 50], [300, 100], [320, 100], [635, 90]]
}
},
bids: [{
bidder: ‘appnexus’,
params: {
placementId: ‘14149971’
}
},{
bidder: ‘rubicon’,
params: {
accountId: ‘19264’,
siteId: ‘314342’,
zoneId: ‘1604128’
}
},{
bidder: ‘amx’,
params: {
tagId: ‘MTUybWVkaWEuY29t’
}
},{
bidder: ‘oftmedia’,
params: {
placementId: navigator.userAgent.match(/iPhone|android|iPod/i) ? ‘22617692’: ‘22617693’
}
}]
});
European Medicines Agency (EMA) approved the vaccine this Thursday View Prevtyn Betadeveloped by the French laboratory Sanofi Pasteur, as a booster dose against COVID-19 in adults already vaccinated with an mRNA preparation or adenovirus vector.
EMA began evaluating the Sanofi Pasteur license application in March last year, but now its experts have concluded that they have fairly reliable data on the quality, safety and immunogenicity of the drug. vaccine recommend its marketing authorization in the European Union (EU).
“A booster dose of VidPrevtyn Beta is expected to be as effective as Comirnaty (the trade name for Pfizer’s vaccine) in restoring protection against COVID-19″, assured EMA.
Is vaccine It is based on a laboratory-grown version of the spike protein found on the surface of the SARS-CoV-2 beta variant and contains an “adjuvant”, a substance that helps boost the immune response to the vaccine.
effects
The most common side effects observed with this vaccine These were pain at the injection site, headache, muscle or joint pain, general malaise and chills, but they were usually mild and disappeared within a few days after vaccination.
EMA send your recommendations European Commissionwho has the last word in the approval of vaccines in European Union.
If Sanofi Pasteur gets permission, the EU vaccines against COVID-19 developed by a total of seven pharmaceutical companies (Pfizer, Valneva, Novavax, Moderna, AstraZeneca and Janssen), although the EMA is also constantly reviewing data on three other vaccines: Spain’s Hipra, Russia’s Sputnik and China’s Vero Cell, which they have not yet been able to apply for obtaining a license.
Someone who has already applied for support EMA the European license includes SK Chemicals’ lab for its Skycovion vaccine, but it is still being studied and an approval date has not yet been set.
(EFE)
Source: RPP
I’m Liza Grey, an experienced news writer and author at the Buna Times. I specialize in writing about economic issues, with a focus on uncovering stories that have a positive impact on society. With over seven years of experience in the news industry, I am highly knowledgeable about current events and the ways in which they affect our daily lives.